Home Health Mpox: WHO Approves Administration of Jynneos Vaccine for Adolescents
HealthNews

Mpox: WHO Approves Administration of Jynneos Vaccine for Adolescents

241

On Monday, the World Health Organisation (WHO) announced its approval of Bavarian Nordic’s Jynneos vaccine for adolescents aged 12 to 17. This group is considered particularly vulnerable to mpox outbreaks. The vaccine was prequalified by the WHO on October 8, 2024, following its earlier approval for adults.

The approval comes after the European Union authorised the vaccine for adolescents in September. The WHO declared mpox a global public health emergency in August, after a new strain of the virus spread across many countries.

Bavarian Nordic is set to begin clinical trials to assess the vaccine’s safety for children aged two to 12. The trials are expected to start in October. Meanwhile, the U.S. FDA has approved the vaccine for adults.

Another mpox vaccine, LC16, developed by Japan’s KM Biologics, is already approved for use in children but requires a specialised needle for administration.

Read More:

About The Author

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

NewsWorld

Nigerian U.S. Embassy and ICIR Cancel Training on “Foreign Influence” in Nigeria After WAW’s Report, Trump’s Foreign Policy Shift

A controversial U.S.-funded media training programme in Nigeria through the International Centre...

CSS tariff
News

CSS Heads to Moscow for Strategic Consultations with Russia

The foreign ministers of the Confederation of Sahel States (CSS), comprising Burkina...

Angola and DRC conflict
NewsSecurity

DR Congo, M23 Rebels to Hold First Direct Talks in Qatar on 9 April

The Democratic Republic of Congo (DRC) and M23 rebels will hold their...

U-17 Africa Cup
NewsSports

CAF U-17 Nations Cup: Golden Eaglets Absent as Morocco Thrash Uganda in Opener

The TotalEnergies U-17 Africa Cup of Nations is underway in Morocco, and...